Mads Krogsgaard Thomsen, Novo Nordisk Foundation CEO

No­vo Nordisk Foun­da­tion is­sues $200M grant to ap­ply quan­tum com­put­ing to life sci­ences, drug dis­cov­ery

The No­vo Nordisk Foun­da­tion, the large Dan­ish char­i­ty that owns the phar­ma­ceu­ti­cal com­pa­ny of the same name, is mak­ing a quan­tum leap.

Mak­ing a deep in­vest­ment in­to what it be­lieves is the fu­ture of life sci­ences, the foun­da­tion is pony­ing up $200 mil­lion to try to de­vel­op the world’s first quan­tum com­put­er de­signed to de­vel­op new drugs. No­vo is­sued the mon­ey in the form of a grant to launch the “No­vo Nordisk Foun­da­tion Quan­tum Com­put­ing Pro­gramme” in tan­dem with the Uni­ver­si­ty of Copen­hagen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.